Kornimate/medical-research-clean huggingface dataset:
topical 0.5% ivermectin cream for treatment of demodicidosis

Conditions: Demodicidosis; Rosacea

Summary: the purpose of this study is to determine whether 0.5% ivermectin cream is effective in the treatment of demodicidosis (including papulopustular rosacea)


Eligibility criteria:
inclusion criteria: * subjects with clinical and laboratory diagnosis of demodicidosis with symmetrical facial eruption who are willing to comply with study requirements exclusion criteria: * known hypersensitivity to ivermectin. * pregnancy * immunodeficiency such as hiv or immunosuppressive therapy * concomitant use of systemic antibiotics or steroids

Keywords: demodex demodicidosis rosacea ivermectin
safety and immunogenicity of takeda's tetravalent dengue vaccine (tdv) in healthy children

Conditions: Healthy Volunteers

Summary: the purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (tdv) in 4 to 16 years' healthy participants.

the vaccine tested in this study was tdv. this study assessed cellular immune responses and safety up to 3 years post second tdv administration to healthy children aged 4 to 16 years and in dengue endemic regions. the study enrolled 200 participants. participants received: • tdv 0.5 ml subcutaneous (sc) injection into the upper arm at day 1 (month 0) and at day 90 (month 3). this multi-center trial was conducted in panama and philippines. 198 participants received the 2-dose schedule of tdv, and 2 participants received only the first dose of tdv (day 1). participants made multiple visits to the clinic and were contacted at least every week for the entire study duration post first injection.

Eligibility criteria:
main inclusion criteria: 1. is aged 4 to 16 years, inclusive (latin america) or 4 to 8 years, inclusive (asia). 2. are in good health at the time of entry into the study as determined by medical history, physical examination (including vital signs), and clinical judgment of the investigator. main exclusion criteria: 1. febrile illness (body temperature ≥38°c) or moderate or severe acute illness or infection at the time of enrolment. 2. history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose an additional risk to the participant due to participation in the study. 3. receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to day 1 (month 0) or planning to receive any vaccines within 28 days after day 1 (month 0). 4. previous participation in any clinical study of a dengue candidate vaccine, or previous receipt of any dengue vaccines (investigational or licensed).

Keywords: drug therapy
effect of early mobilization on regional lung ventilation assessed by eit

Conditions: Critical Illness; Lung Function Decreased; ICU Acquired Weakness

Summary: changes in pulmonary ventilation and perfusion by eit to out-of-bed activity in critically ill patients

1. eit measurements were performed in icu patients who under out-of-bed activity 2. measurement of eit was taken place at 4 time points: supine position before early mobilization, 30min, 60min during early mobilization, supine positon after early mobilization. all of them were without invasive ventilation. measurements were made in triplicate at all time points.

Eligibility criteria:
inclusion criteria: * adult patients was performed out-of-bed activity in the icu department based on doctor order * age (\> 18 years old) and (\< 90 years old) exclusion criteria: * chest skin is injury and cannot be monitored by eit * the patients or their families refused to participate in the study

Keywords: eit early mobilization
feasibility of monitoring health data in pediatric patients undergoing chemotherapy

Conditions: Pediatric Cancer; Febrile Neutropenia; Chemotherapy-induced Neutropenia; Oncology

Summary: in this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the everion®, by biovotion, zurich) in pediatric patients under chemotherapy for cancer, is studied. feasibility is assessed by the number of patients wearing the device on seven consecutive days for at least 18h/day, what will be measured by monitored heart rate. study duration for each participant is 14 days.

no study has proved feasibility of continuous monitoring of health data with a small wearable device such as the device everion® in pediatric patients. it is not known if children tolerate the device and if data quality sustains with smaller arm circumferences or when worn on the upper leg. neither is it known if parents and/or patients can and are willing to handle the device in ambulant setting. therefore, this pilot study assesses the feasibility of continous monitoring of health data with a small, on-skin wearable device (the everion®, by biovotion, zurich) in pediatric patients under chemotherapy for cancer.

Eligibility criteria:
inclusion criteria: * chemotherapy treatment because of any malignancy, expected to last ≥1 months at time of recruitment for myelosuppressive therapy or at least one cycle of myeloablative therapy. * age 1 month to \<18 years at time of recruitment * written informed consent from patients and/or parents exclusion criteria: * local skin diseases prohibiting wearing of the device. * denied written informed consent from patients and/or parent

Keywords: wearable device everion® fever and neutropenia pediatric oncology
minocycline for chronic autoimmune uveitis

Conditions: Minocycline; Uveitis; Retinal Degeneration

Summary: autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. however, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. this trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.


Eligibility criteria:
inclusion criteria: * participant diagnosed of autoimmune diseases with visual function damage (decrease of bcva, loss of retinal structure) * participant aged from 18-60 years old. * participant that signed the informed consent document and is able to complete the following visits. exclusion criteria: * participant is allergy to minocycline or tetracyclines. * participant has no contraindications of minocycline or tetracyclines. * participant has an abnormal function of liver, heart, kidney and thyroid. * participant is using glucocorticoids, immunosuppressants or biologics. * female that is pregnant, breast-feeding or planning to become pregnant. * participant that is currently using other medications for other diseases.
prf therapy for pocket reduction

Conditions: Periodontal Pocket; Periodontitis

Summary: periodontal regenerative therapy has focused on various non-surgical and surgical treatment methods. platelet-rich fibrin (prf) has shown to possess multiple uses, including properties that promote healing of both soft and hard tissues. in the present study, we hypothesized that the addition of prf into periodontal pockets, as an adjunct to conventional scaling and root planing (srp), would enhance the outcomes of non-surgical periodontal therapy. this split-mouth randomized controlled clinical trial included 26 periodontal pocket sites in 13 patients with periodontitis. the pockets were randomly assigned as either test or control sites. in the test group, prf was placed as an adjunct to srp, while the control group received srp alone. probing pocket depths (ppd), clinical attachment levels (cal), gingival recession (gr), plaque index (pi), and gingivitis index (gi) were measured at baseline and at six weeks. the wound healing index was measured during the six-week follow-up period.


Eligibility criteria:
inclusion criteria: * either gender, * aged 18 years or older, * patients without a medical history of systemic diseases, * patient with chronic periodontitis * patient with 5 or 6 mm of probing depth exclusion criteria: * patients with medical history of systemic disease or bleeding disorders * presence of other gingival diseases (such as leukoplakia, lichen planus, pemphigoid disorders, pemphigus vulgaris, herpetic lesions, necrotizing ulcerative periodontitis (nup) * pregnancy * history of any drug usage affecting the periodontium for the past six months (such as systemic antibiotic therapy) * previous periodontal treatment in the last six months * smoking * teeth with untreated caries * endodontic lesions and grade ii or more mobility * subjects with acute exacerbation of periodontitis * patients with systemic * disease or condition that could affect tissue healing (e.g., autoimmune disease) * severe furcation involvement (grade ii and iii) * abutment for prosthetic rehabilitation * active orthodontic therapy
newborn head molding and later asymmetries

Conditions: Plagiocephaly

Summary: prospective randomized clinical interventional trial after birth in maternity ward, and follow up to 8-9 years of age. hypothesis: preventive handling and caring advices to parents of newborns decrease craniofacial asymmetries (deformational plagiocephaly and torticollis). the minimum sample size of the study was calculated at 86 (43 in each arm) using a 5% significance level, a power of 80% and a fall in the prevalence of dp from 31% to 8%. craniofacial asymmetries and appearances of occlusal defects are followed up to 9 years. 50 preterm infants can participate without intervention.

the amount of craniofacial abnormal molding after birth in newborns and the frequency of plagiocephaly in infancy or later consequences of those in childhood are not known in finnish population. head malposition and deformational plagiocephaly, however, have been linked to delayed development in early life and even much later to orthognathic problems demanding surgery in adulthood. in this study parents with healthy newborns are randomized to have normal discharge home or discharged with extra advice information for caregivers; to charge both sided feeding and handling habits; to change regularly sleeping and lying positions; to have early tummy times. anthropometric measurements of the infants; tilting degrees of the head and rotations of the neck (range of movement =rom) are taken at discharge home and at the age of 3 and 6 months, and 1, 3, 5-6 and 8-9 years. two-dimensional digital photographs (upto the age of 6 months) and three-dimensional imaging (from the age of 3 months) are taken to measurements of the head shape (cephalic index=ci and (approximate) oblique cranial length ratio= (a)oclr measured using a semiautomated, computer-based method). the development quotient by griffiths scales are assessed at the age of 3 and 6 months. dental occlusal defect evaluation are started at the age of 3 ys.

Eligibility criteria:
inclusion criteria: * 1-6 days after birth; * healthy newborns in maternal ward, and living in near by oulu region. * preterms at the age of 34-44 gestation weeks in near by oulu region (non randomized) exclusion criteria: * congenital anomalies, * very early discharge, * parental refusal

Keywords: plagiocephaly torticollis occlusal defect
the role of bexarotene in inducing susceptibility to chemotherapy in metastatic tnbc

Conditions: Metastatic Triple-Negative Breast Carcinoma

Summary: triple-negative breast cancer (tnbc) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. cell state transitions, e.g. epithelial-to-mesenchymal transition (emt) govern cancer cell behaviour. the investigators hypothesize that by inducing change in cell state change, tnbc cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically proven metastatic tnbc * patients whose tnbc has progressed after prior taxane therapy in the (neo)adjuvant or metastatic setting, and have not received capecitabine or 5-fluorouracil * females aged 21 years and older * ecog performance status 0 or 1 * life expectancy greater than three months * patients have normal organ and marrow function * site(s) of disease amenable to serial bedside biopsies before, during and after study treatment exclusion criteria: * previous palliative radiotherapy to potentially biopsy-able lesion * active symptomatic central nervous system (cns) metastases * spinal cord compression not definitively treated with surgery and/or radiation * uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures

Keywords: bexarotene
antibiotic impregnated bone graft to reduce infection in hip replacement.

Conditions: Arthroplasty, Replacement, Hip; Osteoarthritis, Hip; Antibiotic Resistant Infection; Prosthetic Joint Infection

Summary: total hip replacement is the most successful treatment modern healthcare can offer patients to regain quality of life. periprosthetic joint infection (pji) is the most common and devastating complication after total hip replacement (thr). between 0.5 to 2% of primary thr (first time hip replacement), and 8-10% of revision thr (replacement of a hip prosthesis) will become infected.1 the introduction of local antibiotics blended into bone cement has led to a reduction in postoperative infection in primary thr by half.2 unfortunately, cement can't always be used in relevant quantities. the number of primary and revision surgeries of the hip is projected to increase dramatically. therefore, the need for a feasible infection prophylaxis that is applicable for complex primary and revision thr in addition to antibiotics loaded cement is urgent. impacted morselized bone allograft is often used in (revision) thr to fill bone defects. morselized allograft has been used as a carrier for local antibiotic treatment in multiple pilot studies and appears to be an attractive and effective treatment option, both for already infected joints and as a prophylactic measure in high-risk patients (e.g. thr revision surgeries). nonetheless, a pivotal trial to support its use in thr is lacking. the aim of this pragmatic randomized controlled double blinded drug trial is to investigate whether antibiotic impregnated bone graft (aibg) decreases the risk of infection after hip arthroplasty compared to controls treated with placebo impregnated bone graft. patients scheduled for elective thr will be randomized to receive aibg or a placebo impregnated bone graft. the primary outcome variable will be the number of re-operations due to infections and pji diagnoses 2 years postoperative.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. hip arthroplasty requiring bone graft 3. willing to provide informed consent. 4. for women of childbearing potential; a negative pregnancy test prior to reoperation. exclusion criteria: 1. ongoing prosthetic joint infection 2. known allergies and contraindications for the use of vancomycin or tobramycin 3. mental inability, reluctance, or language difficulties that according to investigator judgement, result in difficulty understanding the meaning of study participation 4. expected difficulties to complete 2-year follow-up 5. women of child bearing potential not using contraception 6. pregnant women 7. nursing women
evaluation of the effect of custom compression garments on standing static balance in ehlers danlos syndrome

Conditions: Ehlers-Danlos Syndrome

Summary: studies have shown the existence of a proprioceptive deficit in patients with ehlers danlos syndrome (eds) (genetic pathology of connective tissue with hypermobility, multifactor joint instability). a study dating from 2010 showed a qualitative improvement in disability when wearing compression garments (cg) in this pathology, particularly in the fields of proprioception and balance. the purpose of this study is to quantify the effect of cg on standing static balance in patients with eds.

to evaluate the effect of cg on standing static balance in patients with eds, this study is a pilot study, carried out according to a cross-over scheme of type ab/ba. each patient will benefit from 2 posturological evaluations, namely without cg (treatment a) and with cg (treatment b). patients will be randomly assigned to 2 groups: the ab or ba sequence will be randomized for each patient. for each evaluation, a measurement with eyes open and eyes closed will be performed. a clinical balance assessment by the berg test will be performed for each of the conditions.

Eligibility criteria:
inclusion criteria: * eds patients over 18 years of age walking around without technical assistance. * patients will need to be diagnosed both during the interview (presence of a family history, hypermobility and joint instability that has been evolving for years) and with a guide for analysis from eds to ap-hp. * beighton's score must be 5/9 or higher. * free from any other pathology likely to have an impact on the balance. * patient with a cg as part of his or her management of the eds * sufficient understanding to understand the objectives of the study and give consent. * patient affiliated or benefiting from a social security scheme * allergies to one of the components (polyamide and elastane) of the cg * recent compression garments less than 6 months old. exclusion criteria: * patient under guardianship, curators, justice protection. * comorbidity likely to influence balance. * significant pain (assessed by the patient) induced by the use of cg. * any acute event requires the postponement of the assessment to ensure that the patient's progress is in the usual conditions. * any acute pathology having an impact on the musculoskeletal system and/or general condition. * pregnancy/breastfeeding * compression garments over 6 months old.

Keywords: ehlers-danlos syndrome static balance custom compression garments
the application effect of modified pressure-reducing fixation protective nasal strip in the nursing care of patients receiving high-flow nasal cannula therapy

Conditions: High-Flow Nasal Cannula Therapy

Summary: this study was a prospective, randomized controlled trial that included 60 patients receiving high-flow nasal cannula (hfnc) therapy. participants were randomly divided into two groups: the observation group (n=30), which used a modified decompression fixation protective patch, and the control group (n=30), which received hydrocolloid dressing protection in addition to standard care. the study compared general demographic data, the interval time between changing fixation straps, the times of adjusting the catheter position, the effectiveness of skin management, the number of ineffective oxygenation attempts, the incidence of adverse events, and patient comfort scores between the two groups.


Eligibility criteria:
inclusion criteria: * 1. meet the diagnostic criteria for respiratory failure, worsening dyspnea, acute exacerbation of chronic obstructive pulmonary disease (copd), bronchitis, pneumonia, and congestive heart failure. * 2. no severe cognitive impairment. * 3. good compliance and being able to actively cooperate with the investigation. * 4. no concurrent metabolic diseases. exclusion criteria: * 1. patients with severe respiratory failure, severe arrhythmias, concurrent pneumothorax, coma upon admission, or persistent vomiting. * 2. patients with severe liver failure, kidney failure, or other severe systemic diseases. * 3. patients with severe cognitive impairment who are unable to understand or comply with the study requirements. * 4. patients with severe hemodynamic instability. * 5. patients with allergies to oxygen therapy or protective patch materials.

Keywords: hfnc pressure ulcer patient comfort modified pressure-reducing fixation protective nasal strip nursing efficacy
prospective evaluation among patients infected by hiv 1 in virological failure owing to lack of compliance, of the benefit in terms of compliance of an optimised antiretroviral treatment with enfuvirtide (fuzeon) associated with two active molecules

Conditions: HIV1 Infection; HIV Infections

Summary: in case of lack of compliance in hiv1 patients, the investigators hope to prove that enfuvirtide injection during almost 3 months, with nurse help at home and therapeutic education may contribute to obtain a good compliance more than 95% in these patients.


Eligibility criteria:
inclusion criteria: * virological failure, more than 18 years, prouved lack of compliance, with no sub-optimal treatment, in ambulatory status. exclusion criteria: * hospitalization,hiv2 infection,pregnancy,preliminary treatment with enfuvirtide,chimiotherapy , opportunistic infection in progress

Keywords: uncompliant patients with virological failure treatment experienced
added value of contrast enhanced spectral mammography, cesm. a pilot study.

Conditions: Breast Cancer

Summary: introduction: to avoid unnecessary mastectomies and reoperations a correct size assessment of malignant lesions in breast is required. sometimes a supplementary mri is therefore recommended. however, at our unit mri is not easily available. contrast enhanced spectral mammography (cesm) has in smaller studies been shown to be equal to mri regarding sensitivity and specificity. size assessment using contrast-based modalities as cesm has also been shown to be significantly more accurate than using mammography. prospective randomized studies using cesm are lacking. aim: the aim of the study is to evaluate the added value of cesm in diagnostics of breast cancer and choice of operation; partial mastectomy or mastectomy. a pilot study of 50 patients will be conducted to prepare for a larger prospective randomized study. method: patients found with breast cancer after diagnostics with mammography, ultrasound and core biopsy, and whom are recommended primary surgery, will be enrolled in the study. a supplementary examination with cesm will be performed. preoperative extent of the malignant lesions are estimated with each modality and is later compared with the extent measured in post-operative pad. data on weight, length, age at menopaus, use of contraceptive pills, hrt or endocrine therapy, breast volume and density is collected, as well as data of diagnosis (ductal or lobular carcinoma), surrounding dcis, histological grade, er, pgr, her2 expression and ki67 index. in this pilot study sensitivity and specificity for each modality is calculated. multivariate analysis will be performed regarding influential factors. pearson correlation coefficient will be calculated for each modality regarding size assessment of the malignant lesions in comparison with definitive pad.


Eligibility criteria:
inclusion criteria: * patients diagnosed with breast cancer and whom are planned for primary surgery * signed informed consent exclusion criteria: * ongoing pregnancy * ongoing lactation * allergy against iodine contrast * treatment with metformin (against diabetes) * renal failure * hyperthyroidism * severe heart condition * myasthenia gravis * implants * inability to understand study information

Keywords: contrast enhanced spectral mammography